AVEO Pharmaceuticals to Present at IBC`s New Frontiers in Cancer Drug Development Conference

CAMBRIDGE, Mass.--(Business Wire)--
AVEO Pharmaceuticals, Inc. today announced that Murray Robinson, Ph.D., senior
vice president, oncology, is scheduled to present at IBC`s New Frontiers in
Cancer Drug Development Conference on Tuesday, August 4, 2009 at 1:40 p.m. (EDT)
at the World Trade Center Boston/Seaport Hotel in Boston, Mass.

Dr. Robinson will give a presentation titled "VEGF Pathway Response Biomarkers
Using Population-based Preclinical Models" in a pre-conference workshop. This
presentation will explore AVEO`s unique translational biology platform that
queries entire populations of genetically engineered tumor models for drug
response.

About AVEO

AVEO is a late-stage biopharmaceutical company focused on the discovery and
development of novel, targeted cancer therapeutics. AVEO`s proprietary,
integrated cancer biology platform enables the company to pursue highly
efficient drug development strategies in oncology that increase the probability
of clinical success and provides a discovery engine for high-value targets and
therapies. This approach has resulted in a balanced pipeline of novel cancer
therapies focused on well-validated targets (VEGFR, EGFR) and promising novel
targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly,
Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec. The company`s lead
product, tivozanib (AV-951), a triple VEGF receptor inhibitor, recently
completed Phase 2 clinical development in patients with metastatic renal cell
cancer and is expected to enter Phase 3 development in 2009. Through a
combination of internal drug discovery and selective in-licensing of targeted
therapeutics, AVEO is building a diversified product pipeline and moving toward
its vision of becoming a fully integrated biopharmaceutical company. For more
information, please visit the company`s website at www.aveopharma.com.

AVEO Pharmaceuticals, Inc.
David Johnston, Chief Financial Officer, 617-299-5000
or
Pure Communications
Caton Lovett, 910-232-7166

Copyright Business Wire 2009